Biocept Inc. AI Partnership Deal with Prognos Inc. Aid Clinical Laboratory

Posted by Deeksha on January 21st, 2019

Rampant adoption of industrial automation to achieve operational efficiency across verticals has gained substantial traction in recent years. Voluminous datasets governing patient monitoring, drug design, and data processing have necessitated adoption of AI in pharma, biotech, and diagnostic industries, thus paving way for significant agreements and partnership deals. A recent business intelligence report titled, ‘Global Artificial Intelligence (AI) Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010 to 2018’ included in the vast database of Market Research Hub (MRH) enumerates recent advances and evaluates their reciprocal implications.

To aid operational precision across pharma, biotech, and diagnostic industries, leading companies are increasingly relying on AI services. The AI market is a fast expanding market with several established players banking on portfolio differentiation to sustain stiff competition from new market entrants. In these lines, leading diagnostic organization Biocept Inc. that offers liquid biopsy tests targeted for efficient therapeutics pertaining cancer treatments has recently inked a partnership deal with Prognos Inc., best known for its services in disease prediction leveraged by AI. The development is expected to offer renewed growth scope in AI adoption in clinical laboratory diagnostics.

Request for sample copy of this report@

Global AI Partnership Deals in Pharma, Biotech, and Diagnostics: Research Scope

This exhaustive research review on global artificial intelligence partnering agreements offers pertinent insights and understanding regarding several partnering deals and agreements inked by veterans in healthcare industry. The report is systematically bifurcated into elaborate chapters and sections featuring core information on potential macro and micro economic factors, besides highlighting other potential drivers such as trends, restraints, and threats that influence growth. Elaborate research derivatives cited in this section of the report entail core market information pertaining milestones and royalties based on stage of development and top deals in terms of maximum value. The report allows readers to navigate across core contributing factors that encourage pharmaceutical companies to ink partnership deals with AI companies. The report also houses top partnership deals based on which aspiring market players can leverage similar tactical excellence to sustain precedence.

The report in its section on dynamic segmentation segregates AI partnering deals market on the basis of deal type, therapy area, technology type, and company type. These veritable insights housed in this section of the report allow readers to navigate across potential areas thus facilitating lucrative business deals.

Browse Full Report with TOC@@

The report in its trailing sections also emphasizes on regional scope, highlighting country specific partnership deals between AI companies as well as healthcare companies. Thorough research elements gleaned in this section of the report allow readers to gauge the efficacy of business strategies in coining lucrative partnership agreements.

Competitive Landscape: Global AI Partnering in Pharma, Biotech, and Diagnostics

In its trailing sections, the report offers a holistic overview of competition spectrum highlighting key players, complete with a summary of their tactical business decisions, recent developments, and market developments in terms of recent acquisitions, mergers, partnerships, and collaborations. A thorough analytical review of these strategies carried out by market players can facilitate core deductions based on which market players can deliver lucrative business decisions and investment deals.  

Like it? Share it!


About the Author

Joined: January 3rd, 2019
Articles Posted: 12,334

More by this author